

List of Proprietary Items For The Project “Treatment of Poor Cancer Patients”

Hayatabad Medical Complex, Peshawar (October 2016)

S. No.	Name of Drug	Name of Company
1	Tab. Nexaver 200 mg	Bayer
2	Tab. Pazopanib 200 mg	GSK
3	Tab. Pazopanib 400 mg	GSK
4	Tab. Lapatinib 250 mg	GSK
5	Tab. Eltrombopag 50 mg	GSK
6	Inj. Topotecan 4 mg	GSK
7	Inj. Octreotide LAR 20 mg	Novartis
8	Inj. Octreotide LAR 30 mg	Novartis
9	Tab. Sunitinib 50 mg	Pfizer
10	Tab. Exemestane 25 mg	Pfizer
11	Inj. Liposomal Cisplatin 150 mg	Amgomed
12	Inj. Cetuximab 100 mg	Merck
13	Inj. Ristova 100 mg	Roche
14	Inj. Ristova 500 mg	Roche
15	Inj. Avastin 100 mg	Roche
16	Inj. Avastin 400 mg	Roche
17	Inj. Herceptin 400 mg	Roche
18	Tab Tarceva 150 mg	Roche
19	Inj. Recormon	Roche
20	Tab. Valgancyclovir	Roche
21	Inj. Cabazitaxel 60 mg	Sanofi-Aventis
22	Tab. Androcur 50 mg	MediPharm

Companies named above should contact Oncology Pharmacist to finalize contract agreement, performance guarantee and supply orders for the medicines required. Orders shall be placed only for the medicines that are required currently. **Those who have not submitted the following requirements must do so immediately in order to finalize the contract:**

1. All the above-mentioned firms shall provide a signed affidavit on Judicial Stamp Paper regarding their proprietary rights for the products mentioned by them.
2. A certificate that their rates shall be valid for 12 months.
3. A certificate that their rates are the lowest/equal to the lowest anywhere quoted in Pakistan in the last 12 months.
4. A certificate regarding the final re-negotiated rate and/or any optional additional activity or tests to be provided free of cost by the firm.